An independent two-stage DCF analysis by a frontier AI model.
Agilent Technologies has successfully transitioned from its HP origins into a powerhouse within the analytical laboratory ecosystem. With roughly $4.4 billion in recent revenue, its core strength lies in its "razor and blades" business model. While selling high-end instrumentation (the razor) is subject to capital expenditure cycles, the real value driver is the recurring stream of consumables, software licenses, and service contracts (the blades) required to keep those labs operational.
This installed base creates immense switching costs. Laboratories are highly reluctant to retrain staff and revalidate methods on competitor equipment. This stickiness affords Agilent pricing power and margin resilience. The DCF analysis suggests the market is underestimating Agilent's ability to generate compounding free cash flows over the next decade, making it a compelling, undervalued prospect.
An 8.0% growth rate assumes Agilent continues to capitalize on its high-margin recurring revenue streams (consumables and services) while navigating cyclical capital expenditure trends in the broader laboratory market.
An 8.5% discount rate reflects Agilent's stable, diverse revenue base and strong balance sheet, offset slightly by its exposure to global macroeconomic cycles and capital spending fluctuations.
A 3.0% terminal rate is appropriate for a mature, industry-leading provider of mission-critical scientific tools, aligning with long-term economic expansion.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 2.0% | $157.06 | $128.50 | $108.73 | $94.23 | $83.15 |
| 2.5% | $176.69 | $141.35 | $117.79 | $100.96 | $88.34 |
| 3.0% | $201.93 | $157.06 | $128.50 | $108.73 | $94.23 |
| 3.5% | $235.58 | $176.69 | $141.35 | $117.79 | $100.96 |
| 4.0% | $282.70 | $201.93 | $157.06 | $128.50 | $108.73 |
■ Undervalued vs current price ■ Overvalued vs current price
Agilent Technologies, having spun out from Hewlett-Packard, commands a powerful position providing instruments, software, services, and consumables for laboratories. Generating roughly $4.4 billion in recent revenue, its deep integration into customer workflows provides a significant and durable economic moat. Despite near-term macroeconomic choppiness, its long-term prospect remains strong due to its sticky customer base and mission-critical products.
Agilent demonstrates resilient competitive momentum within the analytical laboratory market. Its balanced portfolio of hardware and high-margin consumables ensures steady performance through economic cycles.
Agilent's moat is built on high switching costs inherent in laboratory operations, where revalidating methods and retraining staff on new equipment is prohibitively expensive and risky.
Market sentiment views Agilent as a "pick-and-shovel" play on broad scientific research and industrial testing, appreciating its diverse end-market exposure.
Growth is driven by a strategic shift toward higher-margin recurring revenues. As the installed base of instruments grows, the corresponding demand for high-margin consumables and services increases structurally.
Yes. Agilent's diverse end-markets (ranging from pharma to environmental testing) mitigate sector-specific downturns, while secular trends in global testing standards support mid-to-high single-digit long-term growth.
The market occasionally over-penalizes Agilent for short-term softness in capital equipment orders, underappreciating the stability and cash generation of its underlying recurring revenue model.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.